Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO Antoniotti C., Cremolini C., Loupakis F., Bergamo F., Grande R., Tonini G., Garattini S.K., Masi G., Battaglin F., Lucchesi S. 6 , Salvatore L., Corsi D., Di Fabio F., Banzi M., Sensi E., Tomcikova D., Fontanini G., Zagonel V., Boni L., Falcone A. The role of maintenance following chemotherapy + an anti-EGFR agent is not well established, as well as the optimal maintenance regimen to be adopted.
Statistics Primary endpoint: 10 months-Progression Free Rate (10m-PFR).
The combination of mFOLFOXIRI and cetuximab for 4 months, followed by maintenance treatment with the biologic drug until PD, will be considered promising if the 10m-PFR will increase from 50% to 70% in KRAS wt pts.
• Null hypothesis -10m-PFR: 50%
• Alternative hypothesis -10m-PFR: 70%
• Alpha error: 0.05, Beta error: 0.10 • Design: Fleming single-stage 53 patients per arm (106 total) will be enrolled.
The treatment of each arm will be considered promising if at least 33 pts per arm will be alive and progression-free at 10 months. Neither of the two arms met the primary endpoint (10m-PFR).
RAS
Four months-induction with the modified FOLFOXIRI plus cet schedule we used:  is feasible in a multicentric setting;  shows an acceptable safety profile that favourably compares with data reported with doublets plus anti-EGFR and triplet plus bev;
 has a relevant activity, leading to high conversion rate, that may positively affect OS, still immature.
Data about the impact of maintenance are still pending. Clinical Colon Cancer
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